Buy these 2 ASX health-tech shares that are ready to rocket: Wilson
The health sector is seen by many experts as one that could remain resilient through times of economic distress.
After all, people may cut out dining out or buying a new sofa, but they will still want to remain physically and mentally well.
And with interest rate rises now biting Australian consumers hard, that scenario is well and truly in play.
Here are two ASX shares involved in healthcare that Wilson Asset Management analysts are rating as buys at the moment:
‘Momentum is really strong’
The Aroa Biosurgery Ltd (ASX: ARX) has amazingly rocketed almost 46% over the past 12 months, over a time when few non-mining stocks can even claim to be in the black.
Wilson equity dealer William Thompson reckons that trend will continue, calling it a buy.
“It posted a really good sales update in January,” Thompson said in a Wilson video.
“They’re a New Zealand-based company⦠They have about seven different products which they’re selling in the US.”
Aroa Biosurgey is involved in a joint venture with US partner TELA Bio Inc (NASDAQ: TELA), whose reporting next week could prove to be yet another catalyst for the ASX stock.
With a March year end, Aroa’s annual result is not far away.
“The momentum is really strong for the company, so it’s a buy.”
Thompson’s peers unanimously agree, with all five analysts surveyed on CMC Markets currently rating Aroa Biosurgery as a buy.
This stock could go anywhere now that supply problems are waning
Resmed CDI (ASX: RMD) has been an old favourite for health investors for decades now, but the share price has struggled in recent times.
Over the past 18 months the stock has lost more than 21% of its value.
According to Wilson equity analyst Anna Milne, the troubles for the business are temporary.
“They’ve been really struggling to get [computer] chips,” she said.
“Now as the broader demand for electronics wanes in this more challenging environment, [Resmed] will find it a lot easier to get these semiconductor chips.”
So once that supply problem is fixed, the sky’s the limit for the sleep apnoea device market leader.
That’s because its nearest rival, Koninklijke Philips NV (AMS: PHIA), was forced out due to a safety recall just under two years ago.
“With their major competitor Philips still largely out of the market, and will at least be distracted for a few years, we think Resmed is a great company at a fair valuation.”
The post Buy these 2 ASX health-tech shares that are ready to rocket: Wilson appeared first on The Motley Fool Australia.
FREE Guide for New Investors
Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…
For over a decade, we’ve been helping everyday Aussies get started on their journey.
And to help even more people cut through some of the confusion “experts'” seem to want to perpetuate – we’ve created a brand-new “how to” guide.
*Returns as of March 1 2023
More reading
- Buy these ASX growth shares this week: experts
- Buy these ASX growth shares now: analysts
- 5 ASX 200 shares that inflation can’t touch: expert
- Hereâs why experts rate these ASX 200 growth shares as buys
- Buy these excellent ASX 200 healthcare shares: Goldman Sachs
Motley Fool contributor Tony Yoo has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
